Sofie Wilgenhof - Concepedia

Author

Sofie Wilgenhof

Universitair Ziekenhuis Brussel ORCID

Also Known As

S. Wilgenhof, Sofie Wilgenhof, Wilgenhof, Sofie

165

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Universitair Ziekenhuis Brussel The Netherlands Cancer Institute Vrije Universiteit Brussel Oncode Institute Novartis (Switzerland)

About

Sofie Wilgenhof is an author at Universitair Ziekenhuis Brussel specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	32	2.4K
2	Health Sciences	4	4	198
3	Allergy	2	2	165
4	Nursing	1	1	22
5	Public Health	1	1	22

Sofie Wilgenhof

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings, Nature Medicine Tumor ImmunologyBreast OncologyCancer ImmunosurveillancePd-1 BlockadeMedicine	2019	854
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, New England Journal of Medicine	2022	474
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Clinical Cancer Research	2021	335
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Journal of Clinical Oncology	2016	302
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients Sofie Wilgenhof, An M. T. Van Nuffel, Daphné Benteyn, Annals of Oncology Phase Ib StudyTranslational MedicineDendritic Cell ImmunotherapyMelanomaImmunology	2013	195
Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient Sofie Wilgenhof, Bart Neyns Annals of Oncology Autoimmune DiseaseMelanoma PatientMedicineMelanomaImmunology	2011	173
Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma Sofie Wilgenhof, An M. T. Van Nuffel, Jurgen Corthals, Journal of Immunotherapy ImmunodeficienciesImmunologyImmune RegulationImmunoeditingImmunotherapeutics	2011	152
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma Brenda De Keersmaecker, Sofie Claerhout, Javier Carrasco, Journal for ImmunoTherapy of Cancer	2020	147
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Journal of Translational Medicine	2016	136
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor Amélie Clémentine Seghers, Sofie Wilgenhof, Célèste Lebbé, Melanoma Research Mutant BrafBraf GeneMedicineMelanomaImmunology	2012	123

Page 1